Use of a physiologically based pharmacokinetic model for rats to study the influence of body fat mass and induction of CYP1A2 on the pharmacokinetics of TCDD.
about
Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responsesBayesian Analysis of a Lipid-Based Physiologically Based Toxicokinetic Model for a Mixture of PCBs in RatsPreliminary physiologically based pharmacokinetic models for benzo[a]pyrene and dibenzo[def,p]chrysene in rodentsPersistent organic pollutants in adipose tissue should be considered in obesity research.An assessment of dioxin exposure across gestation and lactation using a PBPK model and new data from Seveso.Maternal dioxin exposure combined with a diet high in fat increases mammary cancer incidence in mice.Childhood obesity and environmental chemicals.Apparent half-lives of dioxins, furans, and polychlorinated biphenyls as a function of age, body fat, smoking status, and breast-feedingMetabolic outcome of female mice exposed to a mixture of low-dose pollutants in a diet-induced obesity model.Inflammatory pathway genes belong to major targets of persistent organic pollutants in adipose cells.Isomer pattern and elimination of dioxins in workers exposed at a municipal waste incineration plantElimination rates of dioxin congeners in former chlorophenol workers from Midland, MichiganToxicological function of adipose tissue: focus on persistent organic pollutants.Mouse breast cancer model-dependent changes in metabolic syndrome-associated phenotypes caused by maternal dioxin exposure and dietary fat.Toxicogenomic evaluation of long-term hepatic effects of TCDD in immature, ovariectomized C57BL/6 mice.Dietary fat alters body composition, mammary development, and cytochrome p450 induction after maternal TCDD exposure in DBA/2J mice with low-responsive aryl hydrocarbon receptors.In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment.Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.Application of pharmacokinetic modelling for 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure assessment.Scientific statement on the health-based guidance values for dioxins and dioxin-like PCBsAryl Hydrocarbon Receptor Antagonists Mitigate the Effects of Dioxin on Critical Cellular Functions in Differentiating Human Osteoblast-Like Cells.
P2860
Q24613799-73D191ED-AFAB-4E41-9B23-33F44037773EQ27496000-818EC337-ED52-4CAC-BA0C-25617B46E308Q28742140-A60CD9FD-FE73-4426-AFCE-C67946A57806Q30240226-D3FC73B6-82E2-4B11-AA54-E04CB0909469Q31068651-0D041402-17F0-44B9-BDFA-17EFAD113896Q33837788-7F93F79F-5BA0-4CAA-9E73-895DB015E4F0Q34789938-5EBB5192-9789-4359-9C04-78EF6F57A349Q34972720-1D2E9C10-57E3-4E71-8F37-F83AF392B58AQ35535741-4D822C0A-171B-410A-BECF-EBE23DDEAA31Q35920258-4B50DB8F-3DDE-44D7-A90A-5357A66462FEQ36113298-362107EC-DEF8-49E5-A06D-6AED1AB312ECQ36556073-BBE74D94-E2C8-49F5-AAF3-24A5F74AA435Q36602294-957FDEFC-BE9F-453F-AEC3-5F0DC2B9FED8Q37086425-E0BF95D1-212A-4109-ACA6-0A1B0D3874FCQ37253515-C78771CE-461A-44F8-A8F6-EF6121614C38Q37331186-F62FDA20-68D0-4F65-B12C-E96902CDCDCAQ42871357-E16BF0A8-B3C4-4FB4-907B-19DA1B8CE215Q44019028-8028C095-A88C-4A8A-84BD-8A739C092792Q46186790-9B46A066-92D8-4B7F-8634-9362398D29CAQ47157010-11CE1F31-A12E-48D2-8C9D-F2FA3B2D3410Q49476204-9AE732FC-C544-41D5-9958-0926A3F414E8
P2860
Use of a physiologically based pharmacokinetic model for rats to study the influence of body fat mass and induction of CYP1A2 on the pharmacokinetics of TCDD.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Use of a physiologically based ...... the pharmacokinetics of TCDD.
@ast
Use of a physiologically based ...... the pharmacokinetics of TCDD.
@en
type
label
Use of a physiologically based ...... the pharmacokinetics of TCDD.
@ast
Use of a physiologically based ...... the pharmacokinetics of TCDD.
@en
prefLabel
Use of a physiologically based ...... the pharmacokinetics of TCDD.
@ast
Use of a physiologically based ...... the pharmacokinetics of TCDD.
@en
P2860
P356
P1476
Use of a physiologically based ...... n the pharmacokinetics of TCDD
@en
P2093
Claude Emond
P2860
P304
P356
10.1289/EHP.8805
P577
2006-09-01T00:00:00Z